Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Entrectinib Monotherapy - Adult, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors	1
For the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who: (i) have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib
Sensitivity (+)	v::NTRK1	Any solid tumor	Entrectinib
Sensitivity (+)	v::NTRK2	Any solid tumor	Entrectinib
Sensitivity (+)	v::NTRK3	Any solid tumor	Entrectinib